Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV ‐INHIBITION study design
ConclusionsThe SV ‐INHIBITION study aims to answer the question whether PDE5 inhibitors should be prescribed in patients with an SV. This trial has been built focusing on the three levels of research defined by the World Health Organization: disability (exercise tolerance), deficit (SV function), and handicap (qual ity of life).
Source: ESC Heart Failure - Category: Cardiology Authors: Pascal Amedro,
Arthur Gavotto,
Hamouda Abassi,
Marie ‐Christine Picot,
Stefan Matecki,
Sophie Malekzadeh‐Milani,
Marilyne Levy,
Magalie Ladouceur,
Caroline Ovaert,
Philippe Aldebert,
Jean‐Benoit Thambo,
Alain Fraisse,
Marc Humbert,
Sara Tags: Study Design Source Type: research
More News: Cardiac Catheterization | Cardiology | Disability | Heart | Heart Disease | Heart Failure | International Medicine & Public Health | Sports Medicine | Stroke | Study | Viagra | WHO